Targeting focal adhesion kinase (FAK) in non-small cell lung cancer (NSCLC): Molecular mechanisms and combination therapeutic strategies.

PPP4C restores YAP1 activity by modulating MST4 phosphorylation to enhance immunosuppression and augment tumor growth in non-small cell lung cancer.

Although surgical resection is the standard of care for early-stage non-small cell lung cancer, frailty influences treatment decisions. We evaluated the prognostic utility of the Veterans Affairs Frailty Index, a claims-based assessment tool, among veterans undergoing resection for stage I non-small cell lung cancer. We conducted a retrospective cohort study of veterans who underwent curative-intent surgery for stage I non-small cell lung cancer in the Veterans Health Administration from 2006 to 2020. Using the Veterans Affairs Frailty Index, frailty was categorized as follows: nonfrail (≤0.1), prefrail (0.1-0.2), mildly frail (0.2-0.3), moderately frail (0.3-0.4), and severely frail (>0.4). The primary outcome was overall survival, assessed using multivariable Cox regression. Secondary outcomes included major complications, prolonged hospitalization, 30-day readmission, 90-day mortality, and recurrence. Among 12,271 veterans, 7.7% were severely frail. Compared with nonfrail patients, severely frail patients were older (mean age 70.3 years vs 64.7 years; P < .001) and were more likely to undergo minimally invasive surgery (57.7% vs 37.8%) and sublobar resection (41.2% vs 22.3%) (all P < .001). Severe frailty was independently associated with higher risk of major complications (adjusted odds ratio 2.85, 95% confidence interval 2.18-3.71), prolonged hospitalization (adjusted odds ratio 2.67), 30-day readmission (adjusted odds ratio 1.76), 90-day mortality (adjusted odds ratio 2.87), and worse overall survival (adjusted hazard ratio 2.20, 95% confidence interval 1.97-2.46; all P < .001). Recurrence was not significantly associated with frailty (adjusted hazard ratio 0.87; P = .410). Frailty, as measured by the Veterans Affairs Frailty Index, independently predicts adverse postoperative and survival outcomes following resection for stage I non-small cell lung cancer. Preoperative frailty assessment may improve risk stratification and guide surgical decision making.

Quercetagitrin targets EIF3D to activate NCOA4-mediated ferritinophagy-dependent ferroptosis for the treatment of non-small cell lung cancer.

Fufang Banmao Capsule (FBC) is clinically applied in the treatment of non-small cell lung cancer (NSCLC), yet its underlying pharmacological mechanism remains to be fully elucidated. This study aimed to systematically elucidate the pharmacological actions of FBC against NSCLC by integrating network pharmacology and Mendelian randomization approaches. Active components and potential targets of FBC were retrieved from the BATMAN-TCM database, while NSCLC-related therapeutic targets were collected from OMIM, TTD, and DisGeNet. Enrichment analysis and a "Herbs-Ingredients-Targets-Pathways" network were constructed. Core targets were further identified through protein-protein interaction and Mendelian randomization analyses, followed by colocaliza tion tests and molecular docking validation. A total of 152 potential FBC targets for NSCLC were identified, with seven candidates shortlisted. Among these, TNF and PIK3CA emerged as key protective targets (P<0.0025, OR<1). Colocalization analysis suggested possible shared genetic causality of TNF and PIK3CA single nucleotide polymorphisms with increased NSCLC risk. Molecular docking confirmed strong binding interactions between these targets and active FBC compounds such as resveratrol. The findings provide a theoretical foundation and new research directions for further investigation into the anti-NSCLC mechanism of FBC, supporting future innovation in therapeutic strategies.

Exploring synergistic therapeutic potential of Erlotinib and artemisinin in non-small cell lung Cancer (NSCLC) using pharmacological networking and mathematical modeling.

Protein kinase Cι-driven macrophage infiltration mediates immunosuppression in non-small cell lung cancer.

CT-based radiomics for predicting PD-L1 expression status in non-small cell lung cancer using a hybrid machine learning model.

Tumor-Educated Extracellular Vesicle-Derived LINC01116 Drives Non-Small Cell Lung Cancer Progression and Immunosuppression by Sponging miR-3614-5p to Upregulate ARHGAP1.

We compared systematic endobronchial ultrasound-guided transbronchial needle aspiration (S-EBUS-TBNA) [sampling every lymph node (LN) > 5 mm regardless of its appearance on positron emission tomography/computed tomography (PET/CT)] with targeted (T) EBUS-TBNA (sampling only abnormal LNs on PET/CT) for mediastinal staging of locally advanced non-small cell lung cancer (NSCLC). Patients with NSCLC with N2 involvement on PET/CT who underwent S-EBUS-TBNA were retrospectively included. For T-EBUS-TBNA, the results of the samplings of abnormal PET/CT LNs during S-EBUS-TBNA were considered. The percentage of cases where S-EBUS-TBNA diagnosed a larger extent of mediastinal disease compared with T-EBUS-TBNA (upstaging from N2a to N2b/N3 and upstaging from N2b to N3) was estimated. A total of 89 patients were included: 61 had N2a and 28 had N2b on PET/CT. Of the 61 with N2a S-EBUS-TBNA diagnosed N3 disease in 2 cases, N2b in 4, N2a in 43, and N0/1 in 12. These 12 patients underwent video-assisted mediastinoscopy (VAM) that showed N2a involvement in 3 and N0/1 in 9. Of the 28 with N2b, S-EBUS-TBNA proved N3 disease in 2 cases, N2b in 10 cases, N2a in 7, and N0/1 in 9. These nine patients underwent confirmatory VAM that showed N2a in two and N0/1 in 7. S-EBUS-TBNA diagnosed a larger extent of mediastinal disease compared with T-EBUS-TBNA staging in 9% of cases: 4 patients with N3 disease that had N2 on PET/CT and four with N2b that had N2a on PET/CT. In patients with NSCLC, S-EBUS-TBNA diagnoses a larger extent of mediastinal disease compared with T-EBUS-TBNA.

Survival analysis and prognostic factors in advanced NSCLC harboring EGFR PACC mutations: A multicenter retrospective study.

FOSL1 promotes homologous recombination repair and camptothecin resistance via TCOF1-mediated ribosome biogenesis in non-small cell lung cancer.

Lack of impact of antibiotics and proton pump inhibitors on the efficacy of preoperative chemoimmunotherapy in locally advanced non-small cell lung cancer: A multicenter retrospective study.

Patient-reported EORTC QLQ C-30 global health status decline predicts survival after video-assisted thoracoscopic (VATS) lung resection and stereotactic ablative radiotherapy (SABR): A 5year follow-up from the Lilac study.

Prospective serial proteomic analysis uncovers mechanistic pathways of chemotherapy resistance in advanced non-small cell lung cancer.

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.

This study aimed to identify prognostic factors associated with recurrence after anatomical segmentectomy in patients with clinical stage IA1 and IA2 non-small-cell lung cancer (NSCLC). All patients who underwent anatomical segmentectomy for clinical stage IA1 and IA2 NSCLC between January 2018 and January 2020 were included. Recurrence was histologically confirmed, with recurrent tumors presenting histopathological features identical to the primary lung cancer. Baseline clinical and pathological characteristics of patients with and without recurrence were compared using inferential statistical methods. Kaplan-Meier and Cox regression analyses evaluated significant predictors of recurrence over time. A total of 180 patients were retrospectively analyzed (mean age 70.4 ± 7.5 years; 63.9% males; mean follow-up 3.1 ± 0.9 years). Recurrence occurred in 18 patients (10%). Logistic regression analysis indicated that recurrence was 5.1 times more prevalent in patients with tumor size ≥ 1.5cm than in those with tumor size < 1.5cm (odds ratio [OR] 5.1; 95% confidence interval [CI] 1.4-18.4, p = 0.01) and 2.9 times more prevalent in patients with pathological upstaging than in those without (OR 2.9; 95% CI 1.0-8.2, p = 0.04). Kaplan-Meier analysis revealed significant differences in recurrence-free estimates between patients with solid tumors ≥ 1.5cm and those < 1.5cm (p < 0.01) and between those with and without pathological upstaging (p = 0.05). Recurrence after anatomical segmentectomy for stage IA1 and IA2 NSCLC is significantly influenced by tumor size and pathological upstaging, underscoring the importance of tailored surgical strategies and meticulous pathological assessment to optimize long-term outcomes and reduce recurrence risk.

AANG: A natural compound formulation for targeting macrophage-myofibroblast transition in non-small-cell lung carcinoma.

This study evaluated the association between percutaneous transthoracic needle biopsy (PTNB) and recurrence in early-stage non-small-cell lung cancer (NSCLC). A retrospective study was conducted to analyze patients with cT1b-2aN0M0 NSCLC who underwent lobectomy between 2009 and 2021. The exclusion criteria ruled out multiple primary lung cancers and bronchoscopic biopsy. Patients were classified into a PTNB group and a non-biopsy group according to whether they underwent preoperative PTNB. Propensity score-matching was applied, and cumulative incidence of recurrence (CIR) was compared. Fine and Gray competing-risk regression was used to evaluate the association between PTNB and recurrence. Subgroup analyses were conducted according to pathologic stage and the presence of high-risk pathologic features. Of 2208 eligible patients, 674 (30.5 %) underwent PTNB, and 1534 (69.5 %) did not. After propensity score-matching, each group included 416 patients with balanced baseline characteristics. In the matched cohort, the 5-year CIR was significantly higher in the PTNB group (21.1 %; 95 % confidence interval [CI], 18.0-26.1 %) than in the non-biopsy group (13.7 %; 95 % CI, 10.2-17.3 %; P < 0.001). In multivariate competing-risk regression analysis, PTNB was independently associated with increased recurrence risk in models incorporating clinical variables alone (subdistribution hazard ratio [SHR], 1.892; 95 % CI, 1.407-2.545; P < 0.001) as well as in models incorporating both clinical and pathologic variables (SHR, 1.851; 95 % CI, 1.375-2.493; P < 0.001). Subgroup analyses demonstrated that the association between PTNB and recurrence persisted regardless of pathologic tumor-node-metastasis (pTNM) stage and the presence of high-risk pathologic features. Preoperative PTNB was associated with an increased risk of recurrence for patients with early-stage NSCLC.

Arachidonic acid analog AACOCF3 suppresses cPLA2-negative NSCLC cell proliferation by targeting SSRP1 to activate the IFNα/β pathway.